Abstract

This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS :Primary Objectives:1. To determine the therapeutic efficacy of VEGF Trap given intravenously once every two weeks in patients with temozolomide-resistant glioblastoma multiforme at first recurrence as measured by 6-month progression free survival (PFS).2. To determine the safety profile of VEGF Trap in the treatment of malignant glioma patients in this manner. Secondary Objectives:1. To determine the efficacy of this treatment as measured by radiographic response [RR], progression free survival [PFS], time to progression [TTP], and overall survival [OS].2. To characterize the single-dose and repeated-dose pharmacokinetic (PK) profiles of VEGF Trap in these patients.Exploratory Objectives:1. To determine the therapeutic efficacy of VEGF Trap given intravenously once every two weeks in patients with temozolomide-resistant anaplastic glioma at first recurrence as measured by 6-month progression free survival (PFS)

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000865-35
Application #
7718036
Study Section
Special Emphasis Panel (ZRR1-CR-4 (01))
Project Start
2007-12-01
Project End
2008-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
35
Fiscal Year
2008
Total Cost
$3,564
Indirect Cost

  Institution

Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095

  Publications

Ellsworth, G B; Lensing, S Y; Ogilvie, C B et al. (2018) A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus Res 6:11-14
Goldman, Noreen; Glei, Dana A; Weinstein, Maxine (2018) Declining mental health among disadvantaged Americans. Proc Natl Acad Sci U S A 115:7290-7295
Dean, Andy C; Morales, Angelica M; Hellemann, Gerhard et al. (2018) Cognitive deficit in methamphetamine users relative to childhood academic performance: link to cortical thickness. Neuropsychopharmacology 43:1745-1752
Nersesian, Paula V; Han, Hae-Ra; Yenokyan, Gayane et al. (2018) Loneliness in middle age and biomarkers of systemic inflammation: Findings from Midlife in the United States. Soc Sci Med 209:174-181
Glei, Dana A; Goldman, Noreen; Ryff, Carol D et al. (2018) Physical Function in U.S. Older Adults Compared With Other Populations: A Multinational Study. J Aging Health :898264318759378
Stephan, Yannick; Sutin, Angelina R; Bayard, Sophie et al. (2018) Personality and sleep quality: Evidence from four prospective studies. Health Psychol 37:271-281
Green, Shulamite A; Hernandez, Leanna M; Bowman, Hilary C et al. (2018) Sensory over-responsivity and social cognition in ASD: Effects of aversive sensory stimuli and attentional modulation on neural responses to social cues. Dev Cogn Neurosci 29:127-139
Burggren, Alison C; Mahmood, Zanjbeel; Harrison, Theresa M et al. (2017) Hippocampal thinning linked to longer TOMM40 poly-T variant lengths in the absence of the APOE ?4 variant. Alzheimers Dement 13:739-748
Sloan, Richard P; Schwarz, Emilie; McKinley, Paula S et al. (2017) Vagally-mediated heart rate variability and indices of well-being: Results of a nationally representative study. Health Psychol 36:73-81
Chung, Joon (2017) Social support, social strain, sleep quality, and actigraphic sleep characteristics: evidence from a national survey of US adults. Sleep Health 3:22-27

Showing the most recent 10 out of 1085 publications